Want to see HK:1276 full AI Analyst Report?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Price & Analysis

6 Followers

1276 Stock Chart & Stats

HK$63.35

Market closed

HK$63.35

Day’s Range― - ―

52-Week RangeHK$51.30 - HK$95.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.62M

Market Cap

HK$426.11B

Enterprise ValueHK$380.12K

Total Cash (Recent Filing)HK$46.26B

Total Debt (Recent Filing)HK$42.24M

Price to Earnings (P/E)44.8

Beta0.67

Next Earnings

Aug 20, 2026

EPS Estimate

0.44

Next Dividend Ex-DateN/A

Dividend Yield0.36%

Share Statistics

EPS (TTM)1.38

Shares Outstanding258,197,600

10 Day Avg. Volume2,417,952

30 Day Avg. Volume3,618,442

Financial Highlights & Ratios

PEG Ratio2.21

Price to Book (P/B)6.79

Price to Sales (P/S)13.15

P/FCF Ratio50.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$88.58

Price Target Upside39.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)1.63

Revenue Forecast (FY)HK$41.34B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetExtremely low debt relative to equity gives durable financial flexibility: it reduces solvency risk, supports continued R&D funding and capacity to withstand sector shocks, and enables strategic investments or partnerships without forcing capital raises that dilute shareholders.

Strong Cash GenerationHigh absolute operating and free cash flow provide a lasting capacity to fund clinical programs, manufacturing scale-up, capex, and shareholder returns internally. Even modest FCF growth still means the company can self-fund strategy execution and withstand cyclical pressures.

High Profitability And MarginsVery high gross margins and solid net income indicate structural pricing power or favorable product mix in specialty drugs. Durable margins support reinvestment into R&D, margin-backed earnings resilience, and buffer against competitive or pricing headwinds over the medium term.

Bears Say

Moderate Top-line GrowthTop-line expansion is modest, which limits leverage from scale and constrains long-term earnings upside if new product launches or geographic expansion falter. Sustained value creation will require either faster organic growth or successful innovation outperformance.

Modest Free Cash Flow GrowthWhile FCF is large in absolute terms, slow growth reduces the pace at which the firm can expand R&D intensity, add manufacturing capacity, or pursue acquisitions without reallocating existing capital, potentially slowing strategic progress versus faster-growing peers.

Reliance On Margin ExecutionCurrent profitability appears driven more by margin strength than rapid revenue gains. This creates vulnerability: if pricing, cost inflation, reimbursement, or competition erode margins, earnings and cash generation could decline materially absent renewed top-line momentum.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News

Hengrui Pharma Wins NMPA Approval for First 0.1% Water-Free Cyclosporine Eye Drop in China

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ). Jiangsu Hengrui...

23d ago

1276

Hengrui Wins Landmark NMPA Nod for New Lung Cancer Use of PD-L1 Drug

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ). Jiangsu Hengrui...

23d ago

1276

Hengrui Pharma Wins NMPA Nod for New Dalpiciclib Breast Cancer Indication

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) just unveiled an update. Jiangsu Hengrui Pharmaceuticals has...

1M ago

1276

Hengrui Pharma Wins NMPA Approval for First Domestic New-Generation URAT1 Inhibitor

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has issued an update. Jiangsu Hengrui Pharmaceuticals has...

2M ago

1276

Hengrui Pharma seals global collaboration and licensing deal with Bristol-Myers Squibb

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ). Jiangsu Hengrui...

2M ago

1276

Hengrui Pharma Sets Formal Remuneration and Evaluation Committee to Bolster Governance

The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ). Jiangsu Hengrui...

3M ago

1276

Hengrui Pharma Sets Nomination Committee to Tighten Board Governance

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has provided an announcement. Jiangsu Hengrui Pharmaceuticals has...

3M ago

1276

Hengrui Pharma Assumes KiOmed License from Hansoh in Connected Deal

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has shared an announcement. Jiangsu Hengrui Pharmaceuticals has...

3M ago

1276

Jiangsu Hengrui Sets Detailed Mandate for Board Audit Committee

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) has shared an announcement. Jiangsu Hengrui Pharmaceuticals has...

3M ago

1276

Hengrui Pharmaceuticals Posts Double-Digit Profit Growth in Strong Q1 2026

An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ) is now available. Jiangsu Hengrui...

3M ago

1276

1276 FAQ

What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$51.30 and its highest was HK$95.20 in the past 12 months.

What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap is HK$426.11B.

When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 33 days.

How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H released its earnings results on Apr 22, 2026. The company reported HK$0.39 earnings per share for the quarter, beating the consensus estimate of HK$0.375 by HK$0.015.

Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?

According to Wall Street analysts Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays a N/A dividend of HK$0.228 which represents an annual dividend yield of 0.36%. See more information on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H dividends here

What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate is 0.44.

How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding.

What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H reported an EPS of HK$0.39 in its last earnings report, beating expectations of HK$0.375. Following the earnings report the stock price went down -0.075%.

Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:1276

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
HK$88.58 (39.83% Upside)

News Sentiment

Very Bullish

Bullish news 100%
Bearish news 0%

Fundamentals

Return on Equity

13.37%

Trailing 12-Months

Asset Growth

47.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues

Historic Earnings Reports

1276 Stock 12 Month Forecast

Average Price Target

HK$88.58

▲(39.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"HK$52","75":"HK$75","98":"HK$98","63.5":"HK$63.5","86.5":"HK$86.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$97.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$88.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,63.5,75,86.5,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.85,60.892307692307696,63.934615384615384,66.97692307692307,70.01923076923077,73.06153846153846,76.10384615384615,79.14615384615385,82.18846153846154,85.23076923076923,88.27307692307693,91.31538461538463,94.3576923076923,{"y":97.4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.85,60.213846153846156,62.57769230769231,64.94153846153846,67.30538461538461,69.66923076923077,72.03307692307692,74.39692307692307,76.76076923076923,79.12461538461538,81.48846153846154,83.85230769230769,86.21615384615384,{"y":88.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.85,58.63076923076923,59.41153846153846,60.19230769230769,60.973076923076924,61.753846153846155,62.534615384615385,63.315384615384616,64.09615384615384,64.87692307692308,65.65769230769232,66.43846153846154,67.21923076923076,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.613,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.839,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.223,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.491,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.938,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.596,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.002,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.767,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.777,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.667,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >